Oral Microto-Nano Genome-Editing System Enabling Targeted Delivery and Conditional Activation of CRISPR-Cas9 for Gene Therapy of Inflammatory Bowel Disease
ACS Nano · 2024
DOI: 10.1021/acsnano.4c07750 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, 2024. Verfasst von Sicen Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Gene Editing, Inflammatory Bowel Diseases, Genetic Therapy. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Liaoning Revitalization Talents Program, Natural Science Foundation of Liaoning Province.
Abstract (Originalsprache)
The potent CRISPR-Cas9 technology can correct genes in human mutated cells to achieve the treatment of multiple diseases, but it lacks safe and effective delivery systems. Herein, we proposed an oral microto-nano genome-editing system aiming at the enteric excessive level of TNF-α for specific gene therapy of inflammatory bowel disease (IBD). This editing system facilitated the assembly of Cas9/sgRNA ribonucleoprotein (RNP) into nanoclusters (NCs) through the bridging of disulfide bonds. RNP-NCs were subsequently encapsulated within inflammatory cell-targeted lipopolysaccharide-deleted outer membrane vesicles (dOMVs) sourced from Escherichia coli Nissle 1917, which were further shielded by an outer layer of calcium alginate microspheres (CAMs). By leveraging the protection effect of CAMs, the oral administration system withstood gastric acid degradation upon entry into the stomach, achieving targeted delivery to the intestines with high efficiency. As the pH gradually rose, the microscale CAMs swelled and disintegrated, releasing nanoscale RNP-NCs encapsulated in dOMVs into the intestines. These RNP-NCs@dOMVs could traverse the mucosal barrier and target inflammatory macrophages where conditionally activated Cas9/sgRNA RNPs effectively perform genomic editing of TNF-α within the nucleus. Such oral microto-nano genome-editing systems represent a promising translational platform for the treatment of IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China.
- Huzhou Central Hospital, Affiliated Central Hospital Huzhou University, Huzhou, Zhejiang313000, China.
- Department of Pharmacy, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning 121001, China.
- Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education, Shenyang, Liaoning 110016, China.
- School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China.
ORCID-Profile: Zhonggui He, Jin Sun
Förderung
- National Key Research and Development Program of China
- Liaoning Revitalization Talents Program
- Natural Science Foundation of Liaoning Province
- National Natural Science Foundation of China
Zitieren
APA
Lin, S., Han, S., Wang, X., Wang, X., Shi, X., He, Z., Sun, M., & Sun, J. (2024). Oral Microto-Nano Genome-Editing System Enabling Targeted Delivery and Conditional Activation of CRISPR-Cas9 for Gene Therapy of Inflammatory Bowel Disease. ACS Nano. https://doi.org/10.1021/acsnano.4c07750
Vancouver
Lin S, Han S, Wang X, Wang X, Shi X, He Z, et al. Oral Microto-Nano Genome-Editing System Enabling Targeted Delivery and Conditional Activation of CRISPR-Cas9 for Gene Therapy of Inflammatory Bowel Disease. ACS Nano. 2024. doi:10.1021/acsnano.4c07750
BibTeX
@article{Lin2024,
author = {Lin, Sicen and Han, Shuwen and Wang, Xu and Wang, Xinyue and Shi, Xianbao and He, Zhonggui and Sun, Mengchi and Sun, Jin},
title = {Oral Microto-Nano Genome-Editing System Enabling Targeted Delivery and Conditional Activation of CRISPR-Cas9 for Gene Therapy of Inflammatory Bowel Disease},
journal = {ACS Nano},
year = {2024},
doi = {10.1021/acsnano.4c07750}
}
EUVIMED